Related references
Note: Only part of the references are listed.RSV Infection in Neonatal Mice Induces Pulmonary Eosinophilia Responsible for Asthmatic Reaction
Dan Zhang et al.
FRONTIERS IN IMMUNOLOGY (2022)
AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis
Marie-Anne Goyette et al.
CANCERS (2022)
Axl Mediates Resistance to Respiratory Syncytial Virus Infection Independent of Cell Attachment
Dan Zhang et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2022)
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy
Thanigaimalai Pillaiyar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Anna Adam-Artigues et al.
SCIENCE ADVANCES (2022)
AXL kinase inhibitors- A prospective model for medicinal chemistry strategies in anticancer drug discovery
Chinmay Malvankar et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2022)
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
Huiyu Li et al.
CELL REPORTS MEDICINE (2022)
Detection of Viral Infections by Innate Immunity
Michael Carty et al.
BIOCHEMICAL PHARMACOLOGY (2021)
AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells
Shuai Wang et al.
CELL RESEARCH (2021)
The interferon landscape along the respiratory tract impacts the severity of COVID-19
Benedetta Sposito et al.
CELL (2021)
Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis
Ting Shi et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
AXL as a Target in Breast Cancer Therapy
Sierra A. Colavito
JOURNAL OF ONCOLOGY (2020)
Innate Type 2 Responses to Respiratory Syncytial Virus Infection
Allison E. Norlander et al.
VIRUSES-BASEL (2020)
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
Shaokun Shu et al.
MOLECULAR CELL (2020)
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
Ke Gong et al.
NATURE CANCER (2020)
RIG-I-like receptors: their regulation and roles in RNA sensing
Jan Rehwinkel et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Shared and Distinct Functions of Type I and Type III Interferons
Helen M. Lazear et al.
IMMUNITY (2019)
Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
Kayla V. Myers et al.
MOLECULAR CANCER (2019)
Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human Sertoli Cells
Daniel P. Strange et al.
MBIO (2019)
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Chenjing Zhu et al.
MOLECULAR CANCER (2019)
Association of Age at First Severe Respiratory Syncytial Virus Disease With Subsequent Risk of Severe Asthma: A Population-Based Cohort Study
Nusrat Homaira et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Interferon-Stimulated Genes as Enhancers of Antiviral Innate Immune Signaling
Keaton M. Crosse et al.
JOURNAL OF INNATE IMMUNITY (2018)
ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial
Claudia M. Gorcea et al.
FUTURE ONCOLOGY (2018)
Respiratory syncytial virus activates epidermal growth factor receptor to suppress interferon regulatory factor 1-dependent interferon-lambda and antiviral defense in airway epithelium
A. Kalinowski et al.
MUCOSAL IMMUNOLOGY (2018)
AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling
Jian Chen et al.
NATURE MICROBIOLOGY (2018)
Modulation of the host immune response by respiratory syncytial virus proteins
Megan E. Schmidt et al.
JOURNAL OF MICROBIOLOGY (2017)
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
Ting Shi et al.
LANCET (2017)
Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses
Laurent Meertens et al.
CELL REPORTS (2017)
Respiratory syncytial virus: prospects for new and emerging therapeutics
Patricia A. Jorquera et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2017)
The Human Immune Response to Respiratory Syncytial Virus Infection
Clark D. Russell et al.
CLINICAL MICROBIOLOGY REVIEWS (2017)
New insights on the viral and host factors contributing to the airway pathogenesis caused by the respiratory syncytial virus
Margarita K. Lay et al.
CRITICAL REVIEWS IN MICROBIOLOGY (2016)
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Samuel H. Myers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
ISG15 Is Upregulated in Respiratory Syncytial Virus Infection and Reduces Virus Growth through Protein ISGylation
Ruben Gonzalez-Sanz et al.
JOURNAL OF VIROLOGY (2016)
Antiviral Screening of Multiple Compounds against Ebola Virus
Stuart D. Dowall et al.
VIRUSES-BASEL (2016)
EGFR Interacts with the Fusion Protein of Respiratory Syncytial Virus Strain 2-20 and Mediates Infection and Mucin Expression
Michael G. Currier et al.
PLOS PATHOGENS (2016)
AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity
Edward T. Schmid et al.
ELIFE (2016)
Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells
M. Vouri et al.
ONCOGENESIS (2016)
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
Sutapa Sinha et al.
CLINICAL CANCER RESEARCH (2015)
Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge
Jeanne H. Schickli et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Axl Receptor Blockade Ameliorates Pulmonary Pathology Resulting from Primary Viral Infection and Viral Exacerbation of Asthma
Takehiko Shibata et al.
JOURNAL OF IMMUNOLOGY (2014)
Phosphatidylserine receptors: Enhancers of enveloped virus entry and infection
Sven Moller-Tank et al.
VIROLOGY (2014)
TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase
Xiaoping Wang et al.
CANCER RESEARCH (2013)
Enveloped Viruses Disable Innate Immune Responses in Dendritic Cells by Direct Activation of TAM Receptors
Suchita Bhattacharyya et al.
CELL HOST & MICROBE (2013)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
S. Betty Yan et al.
INVESTIGATIONAL NEW DRUGS (2013)
S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
Mike F. Burbridge et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Biology of the TAM Receptors
Greg Lemke
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Host Cell Entry of Respiratory Syncytial Virus Involves Macropinocytosis Followed by Proteolytic Activation of the F Protein
Magdalena Anna Krzyzaniak et al.
PLOS PATHOGENS (2013)
TIM-family Proteins Promote Infection of Multiple Enveloped Viruses through Virion-associated Phosphatidylserine
Stephanie Jemielity et al.
PLOS PATHOGENS (2013)
The TIM and TAM Families of Phosphatidylserine Receptors Mediate Dengue Virus Entry
Laurent Meertens et al.
CELL HOST & MICROBE (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
The Soluble Serum Protein Gas6 Bridges Virion Envelope Phosphatidylserine to the TAM Receptor Tyrosine Kinase Axl to Mediate Viral Entry
Kouki Morizono et al.
CELL HOST & MICROBE (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
A diverse range of gene products are effectors of the type I interferon antiviral response
John W. Schoggins et al.
NATURE (2011)
Identification of nucleolin as a cellular receptor for human respiratory syncytial virus
Farnoosh Tayyari et al.
NATURE MEDICINE (2011)
Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors
Alexis Mollard et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
Sacha J. Holland et al.
CANCER RESEARCH (2010)
Pattern Recognition Receptors and Inflammation
Osamu Takeuchi et al.
CELL (2010)
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
Stephen A. Bustin et al.
CLINICAL CHEMISTRY (2009)
Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
Gretchen M. Schroeder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
AXL is a potential target for therapeutic intervention in breast cancer progression
Yi-Xiang Zhang et al.
CANCER RESEARCH (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
TAM receptors are pleiotropic inhibitors of the innate immune response
Carla V. Rothlin et al.
CELL (2007)
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
D. Mahadevan et al.
ONCOGENE (2007)
Share Paper
